Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country entities : Actinium pharmaceuticals, inc. save search
Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Published: 2023-12-11 (Crawled : 14:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: 6.77%
H: 0.35%
C: -13.38%
positive leukemia
Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO
Published: 2023-09-07 (Crawled : 14:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: 0.0%
H: 0.91%
C: -2.72%
pharma expansion preclinical program trial
Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress
Published: 2023-08-21 (Crawled : 12:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: -0.81%
H: 0.74%
C: -2.12%
pharma presentation
Actinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA)
Published: 2023-05-11 (Crawled : 19:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: -0.83%
H: 0.36%
C: -1.43%
pharma association presentation trial results
Actinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks
Published: 2023-04-28 (Crawled : 13:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: 1.03%
H: 0.68%
C: -0.68%
Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting
Published: 2023-04-19 (Crawled : 14:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: -0.86%
H: 1.73%
C: -0.54%
cancer meeting
Actinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Annual Meeting
Published: 2023-04-19 (Crawled : 14:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: -0.86%
H: 1.73%
C: -0.54%
tumors tumor meeting potential
Actinium Pharmaceuticals, Inc. to Present at Oppenheimer's 33rd Annual Healthcare Conference
Published: 2023-03-15 (Crawled : 13:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: -3.55%
H: 1.08%
C: 0.97%
conference
Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH
Published: 2022-12-12 (Crawled : 14:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: -1.67%
H: 1.7%
C: 0.0%
tp53 treatment aml trial presentation
Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial
Published: 2022-11-03 (Crawled : 14:20) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: 0.42%
H: 4.49%
C: -11.82%
aml trial positive phase 1
Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Published: 2022-09-08 (Crawled : 18:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: 3.99%
H: 7.81%
C: 4.74%
global conference
Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means
Published: 2022-04-25 (Crawled : 12:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: 3.65%
H: 3.23%
C: 2.06%
bone control
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Published: 2022-04-19 (Crawled : 12:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: 0.9%
H: 11.33%
C: 5.07%
trial therapy phase 3
Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa
Published: 2022-04-12 (Crawled : 12:20) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: 24.57%
H: 13.66%
C: -0.46%
commercialization africa
Actinium Pharmaceuticals Presents Preclinical Data at AACR Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor Effect
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: 3.85%
H: 1.67%
C: -2.04%
cd47 preclinical immunotherapy pre-clinical her2- her2
Actinium Announces Two Abstracts Highlighting Combinations of CD47 Targeting Immunotherapy with Targeted Radiotherapies in Solid Tumors and Blood Cancers Accepted for Presentation at Society for Immunotherapy for Cancer (SITC) Conference
Published: 2021-10-01 (Crawled : 14:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: -0.45%
H: 1.47%
C: -2.72%
presentation immunotherapy blood solid tumors therapy cancer iot conference
Actinium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29th
Published: 2021-09-28 (Crawled : 14:15) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: -1.14%
H: 1.36%
C: -3.14%
conference
Actinium Highlights Presence at Targeted Radiopharmaceuticals Summit
Published: 2020-12-09 (Crawled : 16:05) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: 0.54%
H: 0.45%
C: 0.36%
Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH
Published: 2020-12-08 (Crawled : 16:01) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: 5.41%
H: 0.05%
C: -3.92%
trial aml
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.